159 related articles for article (PubMed ID: 33386659)
1. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
Schneider JJ; Galettis P; Martin JH
Br J Clin Pharmacol; 2021 Feb; 87(2):317-325. PubMed ID: 33386659
[TBL] [Abstract][Full Text] [Related]
2. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
3. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
4. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
5. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
6. Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL; McLeod HL
Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
[TBL] [Abstract][Full Text] [Related]
7. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
8. The oral fluorinated pyrimidines.
de Bono JS; Twelves CJ
Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
[TBL] [Abstract][Full Text] [Related]
9. Effects of gender on capecitabine toxicity in colorectal cancer.
Ilich AI; Danilak M; Kim CA; Mulder KE; Spratlin JL; Ghosh S; Chambers CR; Sawyer MB
J Oncol Pharm Pract; 2016 Jun; 22(3):454-60. PubMed ID: 26002954
[TBL] [Abstract][Full Text] [Related]
10. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
11. Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
Schmulenson E; Zimmermann N; Mikus G; Joerger M; Jaehde U
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1407-1422. PubMed ID: 35029518
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Wörmann B; Bokemeyer C; Burmeister T; Köhne CH; Schwab M; Arnold D; Blohmer JU; Borner M; Brucker S; Cascorbi I; Decker T; de Wit M; Dietz A; Einsele H; Eisterer W; Folprecht G; Hilbe W; Hoffmann J; Knauf W; Kunzmann V; Largiadèr CR; Lorenzen S; Lüftner D; Moehler M; Nöthen MM; Pox C; Reinacher-Schick A; Scharl A; Schlegelberger B; Seufferlein T; Sinn M; Stroth M; Tamm I; Trümper L; Wilhelm M; Wöll E; Hofheinz RD
Oncol Res Treat; 2020; 43(11):628-636. PubMed ID: 33099551
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
14. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
[TBL] [Abstract][Full Text] [Related]
15. Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Fantini M; Gianni L; Tassinari D; Nicoletti S; Possenti C; Drudi F; Sintini M; Bagli L; Tamburini E; Ravaioli A
J Oncol Pharm Pract; 2011 Sep; 17(3):288-91. PubMed ID: 20926454
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ
J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.
Moloney M; Faulkner D; Link E; Rischin D; Solomon B; Lim AM; Zalcberg JR; Jefford M; Michael M
Cancer Chemother Pharmacol; 2018 Nov; 82(5):865-876. PubMed ID: 30178115
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Kodali S; Bathini V; Rava P; Tipirneni E
J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
[No Abstract] [Full Text] [Related]
20. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
